Related Experiment Video
Updated: Jul 7, 2026
A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
Published on: February 20, 2021
Targeting RAGE in sepsis
Abstract:
The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena.
Insights
Receptor of advanced glycation endproducts (RAGE) is implicated in sepsis-induced inflammation. Further research is needed to address open issues before anti-RAGE therapies can be used in clinical trials for sepsis.
Area of Science:
- Immunology
- Critical Care Medicine
- Molecular Biology
Background:
- The receptor of advanced glycation endproducts (RAGE) is a key mediator in inflammatory responses.
- RAGE activation leads to sustained signaling through multiple inflammatory pathways.
- Recent evidence suggests RAGE as a potential therapeutic target for sepsis.
Discussion:
- Sepsis involves complex inflammatory cascades where RAGE plays a significant role.
- Targeting RAGE presents a promising avenue for novel sepsis treatments.
- Several critical questions remain unanswered regarding RAGE's precise role in sepsis.
Key Insights:
- RAGE is a multiligand receptor implicated in sustained inflammatory pathway activation.
- RAGE is a potential therapeutic target for managing sepsis.
- Translating anti-RAGE strategies into clinical sepsis trials requires addressing outstanding issues.
Outlook:
- Further investigation into RAGE's specific mechanisms in sepsis is essential.
- Pre-clinical research must resolve current challenges before human trials.
- Developing effective anti-RAGE therapies could revolutionize sepsis management.
